Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): Data from UKLG LY09 (ISRCTN97144519)

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 568-573

  Owadally, W S ^a   Sydes, M R ^b   Radford, J A ^c   Hancock, B W ^d   Cullen, M H ^e   Stenning, S P ^b   Johnson, P W M ^a  

^a Cancer Research UK and NIHR Southampton Experimental Cancer Medicine Centre   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d WESTON PARK HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ABVD; Chemotherapy; Dose intensity; Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 77949593962     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp331     Document Type: Article

References (14)

1. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
2. Santoro A, Bonadonna G, Valagussa P et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
3. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD, and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
4. Johnson PW, Radford JA, Cullen MH et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208-9218.
5. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
6. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-811.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
8. Johnson PWM, Sydes MR, Radford JA et al. Consolidation radiotherapy is associated with improved outcomes after chemotherapy for advanced Hodgkin lymphoma: analysis of results from the UKLG LY09 Trial (ISRCTN97144519). Blood 2008; 112: 368s.
9. Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 2320-2325.
10. Proctor SJ, Mackie M, Dawson A et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795-806.
11. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
12. Hasenclever D, Brosteneau O, Gerike T. Modelling of chemotherapy: the effective dose approach. Ann Hematol 2001; 80: B89-B94.
13. Klimm B, Reineke T, Haverkamp H et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 2005; 23: 8003-8011.
14. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18: 376-380.